Cutaneous leishmaniasis is a major public health problem and causes a range of diseases
from self-healing infections to chronic disfiguring disease. Currently, there is no vaccine for …

Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases
of our time, affecting millions of people worldwide. The treatment of these serious diseases …

Leishmaniasis remains a major public health problem worldwide and is classified as
Category I by the TDR/WHO, mainly due to the absence of control. Many experimental …

Disease progression in response to infection can be strongly influenced by both pathogen
burden and infection-induced immunopathology. While current therapeutics focus on …

Neutrophils play an active role in the control of infections caused by intracellular pathogens
such as Leishmania. In the present study, we investigated the effect of neutrophil depletion …

The presence of an RNA virus in a South American subgenus of the Leishmania parasite,
L.(Viannia), was detected several decades ago but its role in leishmanial virulence and …

Recent progress in sequencing the genomes of several Leishmania species, causative
agents of cutaneous, mucocutaneous and visceral leishmaniasis, is revealing unusual …

The current in vivo models for the utility and discovery of new potential anti-leishmanial
drugs targeting Cutaneous Leishmaniasis (CL) differ vastly in their immunological …

Leishmaniases are a group of diseases caused by protozoa of the genus Leishmania that
affect millions of people worldwide. These diseases are caused by distinct Leishmania …

The principal agent of mucocutaneous leishmaniasis (MCL) is the South American
protozoan parasite Leishmania (Viannia) braziliensis. This organism is generally considered …